Chin J E, Winterrowd G E, Hatfield C A, Brashler J R, Griffin R L, Vonderfecht S L, Kolbasa K P, Fidler S F, Shull K L, Krzesicki R F, Ready K A, Dunn C J, Sly L M, Staite N D, Richards I M
Cell Biology and Inflammation Research, and Drug Development Toxicology, Pharmacia and Upjohn Inc., Kalamazoo, Michigan 49001, USA.
Am J Respir Cell Mol Biol. 1998 Feb;18(2):158-67. doi: 10.1165/ajrcmb.18.2.2565m.
We investigated the effects of in vivo intraperitoneal treatment with the rat monoclonal antibody (mAb), YN1.7.4 (YN1) against intercellular adhesion molecule-1 (ICAM-1) on the ovalbumin (OA)-inhalation-induced infiltration of leukocytes into the airways of OA-sensitized mice. YN1 (100 to 400 microg) given over a period of 72 h dose-dependently reduced the influx of lymphocytes and eosinophils into the bronchial lumen by > 60% and > or = 70%, respectively, when compared with saline or purified rat IgG-treated controls. Alveolar macrophages (AM) in the bronchoalveolar lavage fluid (BALF) were also decreased by > 50%. Lung tissue inflammation as determined by histopathologic examination was reduced. The number of neutrophils in the blood of OA-sensitized mice 3 days after challenge was significantly increased by treatment with YN1. However, at 24 h and 72 h after OA-challenge, the numbers of eosinophils and mononuclear cells in the bone marrow were reduced by YN1 treatment. Additionally, at 72 h after OA-challenge, the numbers of bone-marrow neutrophils were depressed. BALF levels of interleukin-5 (IL-5) and of IgA were lower for YN1-treated mice than for controls. With increasing doses of YN1, the levels of anti-ICAM-1 mAb in the plasma were proportionally increased. To correlate these results with YN1 treatment, blood and BALF T cells and BALF eosinophils were examined with flow cytometry. Blood T cells from YN1-treated mice were unable to bind phycoerythrin (PE)-labeled anti-ICAM- mAb ex vivo. These results implied that ICAM-1 on these cells was bound (occupied) by YN1 administered in vivo. Dose-related decreases were observed in the percentage and mean channel fluorescence (MCF) values of ICAM-1+ BALF T cells and eosinophils. The percentages of CD11a+ or CD49d+ eosinophils were also suppressed. Our data suggest that ICAM-1 is an important molecule involved in the recruitment of leukocytes into the airways of sensitized mice after pulmonary challenge.
我们研究了用抗细胞间黏附分子-1(ICAM-1)的大鼠单克隆抗体(mAb)YN1.7.4(YN1)进行体内腹腔注射治疗,对卵清蛋白(OA)吸入诱导的白细胞浸润到OA致敏小鼠气道中的影响。与生理盐水或纯化的大鼠IgG处理的对照组相比,在72小时内给予YN1(100至400微克)剂量依赖性地减少了淋巴细胞和嗜酸性粒细胞分别超过60%和≥70%流入支气管腔。支气管肺泡灌洗液(BALF)中的肺泡巨噬细胞(AM)也减少了超过50%。组织病理学检查确定的肺组织炎症减轻。用YN1治疗使OA致敏小鼠攻击后3天血液中的中性粒细胞数量显著增加。然而,在OA攻击后24小时和72小时,YN1治疗使骨髓中的嗜酸性粒细胞和单核细胞数量减少。此外,在OA攻击后72小时,骨髓中性粒细胞数量减少。YN1治疗的小鼠BALF中白细胞介素-5(IL-5)和IgA水平低于对照组。随着YN1剂量增加,血浆中抗ICAM-1 mAb水平成比例增加。为了将这些结果与YN1治疗相关联,用流式细胞术检查血液和BALF中的T细胞以及BALF中的嗜酸性粒细胞。YN1治疗小鼠的血液T细胞在体外无法结合藻红蛋白(PE)标记的抗ICAM- mAb。这些结果表明这些细胞上的ICAM-1被体内给予的YN1结合(占据)。观察到ICAM-1+BALF T细胞和嗜酸性粒细胞的百分比和平均通道荧光(MCF)值呈剂量相关下降。CD11a+或CD49d+嗜酸性粒细胞的百分比也受到抑制。我们的数据表明ICAM-1是参与肺部攻击后白细胞募集到致敏小鼠气道中的重要分子。